TY - JOUR
T1 - Blood eosinophil count and prospective annual asthma disease burden
T2 - A UK cohort study
AU - Price, David B.
AU - Rigazio, Anna
AU - Campbell, Jonathan D.
AU - Bleecker, Eugene R.
AU - Corrigan, Christopher J.
AU - Thomas, Mike
AU - Wenzel, Sally E.
AU - Wilson, Andrew M.
AU - Small, Mary Buatti
AU - Gopalan, Gokul
AU - Ashton, Valerie L.
AU - Burden, Anne
AU - Hillyer, Elizabeth V.
AU - Kerkhof, Marjan
AU - Pavord, Ian D.
N1 - Funding Information:
Data acquisition and the analyses were funded by Teva Pharmaceuticals. Access to data from the OPCRD was co-funded by Research in Real-Life Ltd (RiRL, Cambridge, UK). Teva Pharmaceuticals played no part in the collection or analysis of the data or the decision to submit the paper for publication. Employees of Teva Pharmaceuticals had a role in interpretation of the data and review of the manuscript. The research team at RiRL designed the study, did the analyses, and coordinated the writing and revision of the paper in collaboration with all authors. The authors received no funds or honoraria from Teva Pharmaceuticals for participation in the study.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015
Y1 - 2015
N2 - Background: Elevated sputum eosinophil counts predict asthma exacerbations and responsiveness to inhaled corticosteroids but are impractical to measure in primary care. We investigated the relation between blood eosinophil count and prospective annual asthma outcomes for a large UK cohort. Methods: This historical cohort study used anonymised medical record data to identify primary care patients with asthma aged 12-80 years with 2 years of continuous records, including 1 year before (baseline) and 1 year after (outcome) their most recent eosinophil count. Negative binomial regression was used to compare outcome exacerbation rates and logistic regression to compare odds of asthma control for patients with blood eosinophil counts of 400 cells per μL or less versus greater than 400 cells per μL, adjusting for age, sex, body-mass index, smoking status, and Charlson comorbidity index. The study is registered at ClinicalTrials.gov, number NCT02140541. Findings: Overall, 20 929 (16%) of 130 248 patients had blood eosinophil counts greater than 400 cells per μL. During the outcome year, these patients experienced significantly more severe exacerbations (adjusted rate ratio [RR] 1·42, 95% CI 1·36-1·47) and acute respiratory events (RR 1·28, 1·24-1·33) than those with counts of 400 cells per μL or less. They also had significantly lower odds of achieving overall asthma control (OR 0·74, 95% CI 0·72-0·77), defined as limited reliever use and no asthma-related hospital attendance or admission, acute course of oral corticosteroids, or prescription for antibiotics. Exacerbation rates increased progressively with nine ascending categories of blood eosinophil count as compared with a reference category of 200 cells per μL or less. Interpretation: Patients with asthma and blood eosinophil counts greater than 400 cells per μL experience more severe exacerbations and have poorer asthma control. Furthermore, a count-response relation exists between blood eosinophil counts and asthma-related outcomes. Blood eosinophil counts could add predictive value to Global Initiative for Asthma control-based risk assessment. Funding: Teva Pharmaceuticals.
AB - Background: Elevated sputum eosinophil counts predict asthma exacerbations and responsiveness to inhaled corticosteroids but are impractical to measure in primary care. We investigated the relation between blood eosinophil count and prospective annual asthma outcomes for a large UK cohort. Methods: This historical cohort study used anonymised medical record data to identify primary care patients with asthma aged 12-80 years with 2 years of continuous records, including 1 year before (baseline) and 1 year after (outcome) their most recent eosinophil count. Negative binomial regression was used to compare outcome exacerbation rates and logistic regression to compare odds of asthma control for patients with blood eosinophil counts of 400 cells per μL or less versus greater than 400 cells per μL, adjusting for age, sex, body-mass index, smoking status, and Charlson comorbidity index. The study is registered at ClinicalTrials.gov, number NCT02140541. Findings: Overall, 20 929 (16%) of 130 248 patients had blood eosinophil counts greater than 400 cells per μL. During the outcome year, these patients experienced significantly more severe exacerbations (adjusted rate ratio [RR] 1·42, 95% CI 1·36-1·47) and acute respiratory events (RR 1·28, 1·24-1·33) than those with counts of 400 cells per μL or less. They also had significantly lower odds of achieving overall asthma control (OR 0·74, 95% CI 0·72-0·77), defined as limited reliever use and no asthma-related hospital attendance or admission, acute course of oral corticosteroids, or prescription for antibiotics. Exacerbation rates increased progressively with nine ascending categories of blood eosinophil count as compared with a reference category of 200 cells per μL or less. Interpretation: Patients with asthma and blood eosinophil counts greater than 400 cells per μL experience more severe exacerbations and have poorer asthma control. Furthermore, a count-response relation exists between blood eosinophil counts and asthma-related outcomes. Blood eosinophil counts could add predictive value to Global Initiative for Asthma control-based risk assessment. Funding: Teva Pharmaceuticals.
UR - http://www.scopus.com/inward/record.url?scp=84961054838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961054838&partnerID=8YFLogxK
U2 - 10.1016/S2213-2600(15)00367-7
DO - 10.1016/S2213-2600(15)00367-7
M3 - Article
C2 - 26493938
AN - SCOPUS:84961054838
SN - 2213-2600
VL - 3
SP - 849
EP - 858
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
IS - 11
ER -